Mark Lappe
CIK: 0001366074
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Inhibrx Biosciences, Inc.
Discretionary Trading P&L
Holdings
Transaction History (25 total)
- Oct 14, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect2.5K shares at avg. $84.07$208K - Oct 14, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect2.5K shares at avg. $85.00$210K - Oct 14, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect100 shares at avg. $85.76$9K - Oct 14, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect2.4K shares at avg. $84.07$206K - Oct 14, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect2.5K shares at avg. $85.00$208K - Oct 14, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect100 shares at avg. $85.76$9K - Sep 28, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect3K shares at avg. $101.70$305K - Sep 28, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect1.5K shares at avg. $98.88$148K - Sep 25, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect3.3K shares at avg. $98.87$329K - Sep 25, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect2.2K shares at avg. $99.60$217K - Sep 8, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect1.2K shares at avg. $111.88$136K - Sep 8, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect500 shares at avg. $108.23$54K - Sep 8, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect1.1K shares at avg. $107.12$118K - Sep 8, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect6.6K shares at avg. $100.64$665K - Sep 8, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect5.9K shares at avg. $99.29$585K - Sep 8, 2026INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect9.7K shares at avg. $112.28$1.1M - Sep 16, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect13K shares at avg. $17.13$223K - Sep 12, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect27K shares at avg. $15.05$406K - Sep 10, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect8.5K shares at avg. $15.19$129K - Sep 9, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect9.5K shares at avg. $15.21$144K - Sep 6, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect26K shares at avg. $15.29$398K - Sep 3, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect15.3K shares at avg. $15.66$239K - Sep 3, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect4.7K shares at avg. $16.31$77K - Aug 30, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect10K shares at avg. $14.02$140K - Aug 29, 2024INBX
Inhibrx Biosciences, Inc.
Purchase(P)Indirect10K shares at avg. $14.03$140K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 2,470 | $84.07 | $207,655 | Indirect |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 2,470 | $85.00 | $209,948 | Indirect |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 100 | $85.76 | $8,576 | Indirect |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 2,449 | $84.07 | $205,889 | Indirect |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 2,451 | $85.00 | $208,333 | Indirect |
| Oct 14, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 100 | $85.76 | $8,576 | Indirect |
| Sep 28, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 3,000 | $101.70 | $305,106 | Indirect |
| Sep 28, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 1,500 | $98.88 | $148,320 | Indirect |
| Sep 25, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 3,324 | $98.87 | $328,630 | Indirect |
| Sep 25, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 2,176 | $99.60 | $216,727 | Indirect |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 1,219 | $111.88 | $136,382 | Indirect |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 500 | $108.23 | $54,118 | Indirect |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 1,100 | $107.12 | $117,836 | Indirect |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 6,605 | $100.64 | $664,719 | Indirect |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 5,895 | $99.29 | $585,343 | Indirect |
| Sep 8, 2026 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 9,681 | $112.28 | $1,087,001 | Indirect |
| Sep 16, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 13,037 | $17.13 | $223,324 | Indirect |
| Sep 12, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 26,963 | $15.05 | $405,793 | Indirect |
| Sep 10, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 8,500 | $15.19 | $129,115 | Indirect |
| Sep 9, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 9,500 | $15.21 | $144,495 | Indirect |
| Sep 6, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 26,000 | $15.29 | $397,540 | Indirect |
| Sep 3, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 15,288 | $15.66 | $239,410 | Indirect |
| Sep 3, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 4,712 | $16.31 | $76,853 | Indirect |
| Aug 30, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 10,000 | $14.02 | $140,200 | Indirect |
| Aug 29, 2024 | INBX Inhibrx Biosciences, Inc. | Purchase(P) | 10,000 | $14.03 | $140,300 | Indirect |
1-25 of 25 transactions
About Lappe Mark
Lappe Mark (SEC CIK 0001366074) files insider reports with the SEC as Chief Executive Officer of Inhibrx Biosciences, Inc. (INBX).
Signal8 holds 6 ownership filings by Lappe Mark, all Form 4s, filed between Sep 3, 2024 and Oct 14, 2026. Those filings report 25 transactions, from Aug 29, 2024 to Oct 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Lappe Mark's filings is in LA JOLLA, CA.
Recent filings by Lappe Mark
- Oct 14, 2026: Open-market purchases of INBX shares (6 lines, Form 4, code P).
- Sep 28, 2026: Open-market purchases of INBX shares (2 lines, Form 4, code P).
- Sep 25, 2026: Open-market purchases of INBX shares (2 lines, Form 4, code P).
- Sep 8, 2026: Open-market purchases of INBX shares (6 lines, Form 4, code P).
- Sep 16, 2024: Open-market purchase of INBX shares (Form 4, code P).
Other insiders filing for Inhibrx Biosciences, Inc. (INBX)
- Kayyem Jon Faiz, Director
- FORSYTH DOUGLAS, Director
- Vuori Kristiina MD, Director
- MANHARD KIMBERLY, Director
- Matly David, President
- VIKING GLOBAL INVESTORS LP, 10% Owner